Pfizer/$PFE
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
81,000
ISIN
US7170811035
Website
Pfizer Metrics
BasicAdvanced
$136B
17.26
$1.38
0.50
$1.70
7.20%
Price and volume
Market cap
$136B
Beta
0.5
52-week high
$31.54
52-week low
$20.92
Average daily volume
42M
Dividend rate
$1.70
Financial strength
Current ratio
1.258
Quick ratio
0.88
Long term debt to equity
63.9
Total debt to equity
76.181
Dividend payout ratio (TTM)
121.49%
Interest coverage (TTM)
5.58%
Profitability
EBITDA (TTM)
23,506.5
Gross margin (TTM)
74.42%
Net profit margin (TTM)
12.62%
Operating margin (TTM)
26.41%
Effective tax rate (TTM)
-6.90%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
4.79%
Return on equity (TTM)
8.62%
Valuation
Price to earnings (TTM)
17.264
Price to revenue (TTM)
2.167
Price to book
1.53
Price to tangible book (TTM)
-3.79
Price to free cash flow (TTM)
12.065
Free cash flow yield (TTM)
8.29%
Free cash flow per share (TTM)
197.94%
Dividend yield (TTM)
7.12%
Forward dividend yield
7.20%
Growth
Revenue change (TTM)
11.65%
Earnings per share change (TTM)
-2,464.07%
3-year revenue growth (CAGR)
-12.25%
10-year revenue growth (CAGR)
2.43%
3-year earnings per share growth (CAGR)
-31.81%
10-year earnings per share growth (CAGR)
-0.41%
3-year dividend per share growth (CAGR)
2.49%
10-year dividend per share growth (CAGR)
4.78%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Bulls say / Bears say
Pfizer's acquisition of Seagen for $43 billion enhances its oncology portfolio, positioning the company for significant growth in the cancer treatment market. (investing.com)
The European Commission's approval of Pfizer's RSV vaccine, ABRYSVO®, for adults aged 18 to 59 at increased risk, expands the company's vaccine offerings and potential revenue streams. (businesswire.com)
Pfizer's licensing agreement with China's 3SBio for the experimental cancer drug SSGJ-707, including a $1.25 billion upfront payment and potential $4.8 billion in milestones, strengthens its oncology pipeline and global presence. (reuters.com)
The U.S. House Judiciary Committee's investigation into allegations that Pfizer delayed COVID-19 vaccine trial results to influence the 2020 presidential election could damage the company's reputation and lead to legal challenges. (reuters.com)
Pfizer's first-quarter 2025 revenue of $13.72 billion missed expectations, primarily due to a significant decline in Paxlovid sales, indicating potential challenges in maintaining revenue growth post-pandemic. (reuters.com)
The nomination of vaccine skeptic Robert F. Kennedy Jr. as U.S. health secretary poses a potential threat to Pfizer's vaccine sales, as his views could influence public perception and policy decisions. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $136B as of June 20, 2025.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 17.26 as of June 20, 2025.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $1.7 and the yield is 7.2%. Pfizer has a payout ratio of 121.49% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment date is unconfirmed.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.